Skip to main content

Georgia Marie Beasley, MD, MHS

Assistant Professor of Surgery
Office: Dept of Surgery, Durham, NC 27710
Campus Mail: DUMC Erwin Rd, Durham, NC 27710

Education and Training

  • Surgical Oncology Fellow, Surgery, Ohio State University, 2015 - 2017
  • General Surgery Resident, Surgery, Duke University, 2008 - 2015
  • M.H.S., Duke University, 2012
  • M.D., Duke University School of Medicine, 2008
  • B.A., Duke University, 2001

Publications

Beasley, Georgia M., and Douglas S. Tyler. “Standardizing regional therapy: developing a consensus on optimal utilization of regional chemotherapy treatments in melanoma..” Ann Surg Oncol 18, no. 7 (July 2011): 1814–18. https://doi.org/10.1245/s10434-011-1656-9.

Full Text

Beasley, Georgia M., Jonathan C. Riboh, Christina K. Augustine, Jonathan S. Zager, Steven N. Hochwald, Stephen R. Grobmyer, Bercedis Peterson, Richard Royal, Merrick I. Ross, and Douglas S. Tyler. “Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma..” J Clin Oncol 29, no. 9 (March 20, 2011): 1210–15. https://doi.org/10.1200/JCO.2010.32.1224.

Full Text

Augustine, Christina K., Hiroaki Toshimitsu, Sin-Ho Jung, Patricia A. Zipfel, Jin S. Yoo, Yasunori Yoshimoto, M Angelica Selim, et al. “Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy..” Mol Cancer Ther 9, no. 7 (July 2010): 2090–2101. https://doi.org/10.1158/1535-7163.MCT-10-0073.

Full Text

Beasley, G. M., N. McMahon, G. Sanders, A. Coleman, J. Padussis, J. S. Zager, S. N. Hochwald, et al. “Final Results of a Prospective Multi-Center Phase II Trial of Systemic ADH-1 in Combination with Melphalan via Isolated Limb Infusion (M-ILI) in Patients with Advanced Extremity Melanoma.” In Annals of Surgical Oncology, 17:S21–S21. SPRINGER, 2010.

Scholars@Duke

Turaga, K. K., G. M. Beasley, R. J. Gonzalez, K. A. Delman, G. D. Letson, D. Cheong, D. S. Tyler, and J. S. Zager. “Limb Preservation with Isolated Limb Infusion for Unresectable Non-melanoma Cutaneous and Soft Tissue Malignancies.” In Annals of Surgical Oncology, 17:S32–S32. SPRINGER, 2010.

Scholars@Duke

Beasley, G. M., A. Selim, N. S. McMahon, A. Coleman, A. P. Abernethy, K. Nelson, S. K. Pruitt, et al. “Prospective Evaluation of PET/CT as a Surveillance Tool to Define Response to Therapy and Identify New Recurrent Disease in Patients with Locally Advanced Melanoma Undergoing Regional Chemotherapy Treatment with Melphalan.” In Annals of Surgical Oncology, 17:S115–S115. SPRINGER, 2010.

Scholars@Duke

Coleman, Andrew, Christina K. Augustine, Georgia Beasley, Gretchen Sanders, and Douglas Tyler. “Optimizing regional infusion treatment strategies for melanoma of the extremities..” Expert Rev Anticancer Ther 9, no. 11 (November 2009): 1599–1609. https://doi.org/10.1586/era.09.126.

Full Text

Beasley, Georgia M., Nicole McMahon, Gretchen Sanders, Christina K. Augustine, Maria A. Selim, Bercedis Peterson, Robin Norris, William P. Peters, Merrick I. Ross, and Douglas S. Tyler. “A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma..” Cancer 115, no. 20 (October 15, 2009): 4766–74. https://doi.org/10.1002/cncr.24509.

Full Text

Santillan, Alfredo A., Keith A. Delman, Georgia M. Beasley, Paul J. Mosca, Steven N. Hochwald, Stephen R. Grobmyer, Robert H. Andtbacka, et al. “Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis..” Ann Surg Oncol 16, no. 9 (September 2009): 2570–78. https://doi.org/10.1245/s10434-009-0563-9.

Full Text

Pages